

Review Article

PGI₂ as a Regulator of Inflammatory Diseases

Stacy L. Dorris and R. Stokes Peebles Jr.

Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University School of Medicine, T-1218 MCN, Nashville, TN 37232-2650, USA

Correspondence should be addressed to R. Stokes Peebles Jr., stokes.peebles@vanderbilt.edu

Received 8 March 2012; Accepted 24 May 2012

Academic Editor: Nicolas Flamand

Copyright © 2012 S. L. Dorris and R. S. Peebles Jr. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Prostacyclin, or PGI₂, is an end product derived from the sequential metabolism of arachidonic acid via cyclooxygenase and PGI synthase (PGIS). The receptor for PGI₂, IP, can be found on a variety of cell types and signaling through this receptor exhibits broad physiological effects. Historically, PGI₂ has been understood to play a role in cardiovascular health, specifically having powerful vasodilatory effects via relaxation of smooth muscle and inhibiting of platelet aggregation. For these reasons, PGI₂ has a long history of use for the treatment of pulmonary arterial hypertension (PAH). Only recently, its importance as an immunomodulatory agent has been investigated. PGI₂ regulates both the innate and adaptive immune systems and its effects are, for the most part, thought to be anti-inflammatory or immunosuppressive in nature, which may have implications for its further clinical use.

1. Introduction

Prostacyclin, or PGI₂, was first reported by Needleman and Vane in 1976 and is an end product derived from the sequential metabolism of arachidonic acid via cyclooxygenase-2 (COX-2) and prostacyclin synthase (PGIS) [1]. COX-2 is expressed upon specific stimulation such as cytokines, growth factors, bacterial endotoxins, tumor promoters, and hormones by macrophages, neutrophils, and activated mesenchymal cells [2–4]. There is rare expression of COX-2 in unstimulated tissues [5–7], but it can be present at low basal levels in endothelium and the renal macula densa [2, 5]. COX-2 is typically associated with proinflammatory conditions such as atherosclerotic lesions, aortic aneurysms, or vascular damage where COX-2 derived products likely provide a protective effect [8–10]. COX-2 is inhibited by nonsteroidal anti-inflammatory (NSAIDs) and specific COX-2 inhibitors, which may have tissue specific effects.

Several additional cells types have been shown to express COX-2 and PGIS and they include fibroblasts, follicular dendritic cells, endothelial cells, smooth muscle cells, and thymic nurse cells. Production of PGI₂ is decreased by the inhibition of PGIS by tyrosine-nitrating agents such as peroxynitrite [11] and tetranitromethane [12]. Lastly, PGIS

can be limited by substrate-dependent suicide inactivation if there is adequate conversion of PGH₂, the substrate for PGIS, which causes accumulation of inactivated enzyme [13].

PGI₂ is primarily produced in mammalian vasculature with elevated levels in pulmonary arterial segments when compared to systemic circulation [14]. As such, PGI₂ has been understood to play a role in cardiovascular health specifically inhibiting platelet aggregation and having powerful vasodilatory effects via relaxation of smooth muscle [5, 15]. PGI₂ analogues have been successfully used for therapy in pulmonary arterial hypertension, peripheral occlusive disease, vascular complication of diabetes mellitus, and treatment of reperfusion injury. Only recently, its importance as an immunomodulatory agent has been investigated.

2. PGI₂ Receptor Signaling

The cell surface receptor for PGI₂ is a seven transmembrane G-protein-coupled receptor termed IP [6]. IP is coupled to a guanosine nucleotide-binding α -stimulatory protein (G α_s). When activated by PGI₂, IP stimulates adenylyl cyclase leading to increased intracellular cyclic AMP (cAMP) (see Figure 1). Increased cAMP then leads to activation of protein kinase




FIGURE 1: PGI₂ receptor signaling.

A (PKA) and further phosphorylation of key proteins [14–16]. These actions culminate in relaxation of smooth muscle, reduced cell proliferation, and other inhibitory mechanisms. IP is found on a variety of cell types and exhibits broad physiological effects. Mouse IP receptors have been identified on neurons, smooth muscle cells of the aorta, coronary arteries, pulmonary arteries, and megakaryocytes. Human IP receptors are present on multiple cell types including platelets, medullary thymocytes, neutrophils, dendritic cells, eosinophils, T regulatory cells, and activated T cells [4, 17]. IP receptors are also found on many cell types in the lung such as macrophages, pneumocytes, smooth muscle cells, and fibroblasts [17]. In addition to the single known membrane IP receptor, a peroxisome proliferator-activated nuclear receptor (PPAR) functions as a transcription factor after activation by PGI₂ [3, 15]. There are three PPAR isoforms, α , δ (β), and γ [15]. PPAR γ , expressed in adipose tissue, spleen, and large intestines predominately, is thought to be downstream of the activated IP membrane receptor and can be stimulated via stable PGI₂ analogues. PPARs are responsive to not only PGI₂ but also a broad range of ligands [15].

3. PGI₂ in Specific Disease States

3.1. Allergic Inflammation. One of the areas that PGI₂ has been extensively studied is allergic inflammation. PGI₂ is produced in the human lung during allergic reactions, suggesting that it may have a regulatory role in allergen-induced inflammation [18, 19]. The *in vivo* role of PGI₂ in mediating allergic inflammation has been investigated both in IP-deficient mice, which examines the role of endogenous PGI₂ signaling, as well as exogenous administration of PGI₂. First, we will review studies that use IP-deficient mice in determining how endogenous PGI₂ modulates allergen-induced lung disease.

In an acute model of allergic inflammation induced by ovalbumin (OVA), IP-deficient mice had significantly greater airway inflammatory responses consisting of increased plasma extravasation, leukocyte accumulation, and both IL-4 and IL-5 production in the airways after sensitization

and exposure to inhaled antigen [20]. In addition, the IP-deficient mice had elevated total serum IgE and antigen-specific IgE when compared to wild-type mice [20]. These findings support endogenous PGI₂ as an important suppressor of acute allergic inflammation. Similar findings were reported in a chronic model of OVA-induced lung inflammation. In this IP-deficient mouse model, there was a significant increase in the level of inflammatory leukocytes in the airway, serum OVA-specific IgE, and lung expression of T helper type 2 (Th2) cytokines such as IL-4, IL-5, and IL-13. The IP-deficient mice had more subepithelial fibrosis compared to wild-type mice, possibly related to the upregulation of collagen synthesis [21]. Therefore, inability to signal through IP led to enhanced acute and chronic allergic inflammation and airway remodeling.

In addition to IP-deficient mice, the role of COX-2 inhibitors contributes to the knowledge of how endogenous PGI₂ regulates allergic inflammation. After OVA inhalation in a DO11.10 transgenic mouse model of T-cell-mediated airway inflammation, there was an increased level of PGI₂ [4]. Blocking PGI₂ via COX-2 inhibition resulted in a marked increase in Th2 mediated lung inflammation in response to OVA challenge. COX-2 inhibition and the prevention of PGI₂ formation was associated with increased bronchial airway hyperresponsiveness, elevated lung expression of Th2 cytokines, and decreased IL-10 production [4]. These results highlight a possible risk enhanced airway inflammation with use of specific COX-2 inhibitors in allergic asthmatics by blocking production of an immunoinhibitory prostanoid such as PGI₂.

Animal models of exogenous PGI₂ administration further supports that this prostanoid inhibits allergic inflammation. In an OVA sensitized mouse model using adoptive transfer of DO11.10 Th2 cells pretreated with PGI₂, there was significantly decreased pulmonary inflammation and airway hyperreactivity [22]. A protective effect of PGI₂ on acute airway function is further suggested by a null effect on ozone induced airway inflammation and hyperresponsiveness in mPGES-1 deficient mice. PGI₂ metabolites in the BAL of these mice were increased, while changes in other prostanoids favored deleterious effects on lung

function [23]. PGI₂ suppressed Th2 infiltration of the lung via strong inhibition of CCL17-induced chemotaxis. IP deficient Th2 cells were unaffected and migrated normally [22]. Lastly, in a mouse model of asthma, inhaled iloprost, a PGI₂ analogue, decreased the cardinal features of asthma such as Th2 cytokine production, eosinophilic airway inflammation, goblet cell hyperplasia, and bronchial airway hyperresponsiveness [24]. Iloprost inhibited the maturation and migration of antigen presenting lung myeloid dendritic cells, decreased costimulatory molecules, and decreased the induction of allergen-specific Th2 response [24]. These findings suggest a role for inhaled iloprost in the treatment of asthma.

3.2. Inflammation-Induced Anorexia. We have shown that PGI₂ signaling via the IP receptor reduces allergic inflammation. The effect of decreased appetite in acute inflammation, such as in the setting of IL-1 β and lipopolysaccharide (LPS) administration, has been suggested to be PG dependent. In a mouse model, PGI₂ signaling decreased the level of circulating ghrelin, a peptide produced predominantly by the stomach, which has potent stimulatory effects on appetite [25]. This finding was very similar to the effect of LPS on circulating levels of ghrelin and suggests a role for PGI₂ in the acute sickness behavior of anorexia. IL-1 β induced ghrelin expressing cells to produce PGI₂. Nonspecific inhibition of PG production via NSAIDs reversed the decrease in circulating ghrelin caused by the acute inflammatory stimulation of LPS specifically [25]. These results suggest that PGI₂ may suppress appetite in certain acute inflammatory disease states.

3.3. Liver Injury. In a mouse model of a concanavalin-A (ConA-) induced immune-mediated liver injury mimicking hepatic inflammation, beraprost, a PGI₂ analogue, decreased tissue damage [7]. COX-2 deficient mice developed more severe ConA-induced liver damage compared to wild-type mice or COX-1 deficient mice. Treatment with beraprost/ConA had a protective effect with a more than 10-fold decrease in serum alanine aminotransferase (ALT) levels compared to those treated with vehicle/ConA alone. Hepatic mRNA levels and expression of both TNF- α and IFN- γ by natural killer T cells (NKT) and T cells, key in the development of ConA induced liver disease, were decreased in the COX-2 deficient mice after treatment with beraprost when compared to vehicle/ConA alone treated mice. The protection provided by beraprost is postulated to stem from the maintenance of hepatic blood flow via beraprost's vasodilatory effects [7]. These findings suggest that PGI₂ analogues may be of benefit to patients suffering from inflammatory liver disease such as hepatitis due to viral infection, autoimmune conditions, use of certain drugs, or alcohol ingestion.

3.4. Cardiovascular Disease. It is hypothesized that early depletion of PGI₂ from endothelial tissue could lead to the pathogenesis of atherosclerosis by causing deposition of adipocyte lipid in smooth muscle cells [26]. Cellular micro

RNA (miRNA) is an important known negative regulator of gene expression. PGI₂ regulated miRNA expression in a mouse adipose tissue-derived cell line leading to diminished deposition of lipid in cells [15]. The importance of this lies in the possibility of a relationship between loss of normal PGI₂ production in the setting of obesity and atherosclerosis.

Iloprost was investigated for its effects on leukocyte adherence in intestinal venules and subsequent microvascular blood flow in a rat endotoxemia model. Iloprost attenuated leukocyte adherence in both postcapillary and collecting intestinal venules and improved intestinal microvascular blood flow without affecting mean arterial pressure or heart rate [27]. These findings suggest a role for iloprost therapy to reduce endotoxin-induced intestinal injury.

Retinoic acid induces PGIS and therefore synthesis of PGI₂ in human umbilical vein endothelial cells [2]. Retinoic acid is important in the development of the cardiovascular system during embryonic development, angiogenesis and has antithrombotic and antiatherogenic qualities. 13-*cis*-retinoic acid (13-*cis*-RA) a molecule with anti-inflammatory, antitumor, and immunomodulatory effects elevated PGI₂ levels as measured by 6-oxo-PGF_{1 α} . Consistently, arachidonic acid induced platelet aggregation was inhibited by 13-*cis*-RA. Treatment with the inflammatory cytokine IL-1 β alone rapidly inactivated PGIS in these same cells followed by a diminution of PGI₂. These findings support a role for 13-*cis*-RA as a possible selective treatment for patients with inflammatory cardiac disease. When IL-1 β was given in combination with 13-*cis*-RA, 13-*cis*-RA was able to overcome the inhibitory effects of IL-1 β , leading to increased PGIS expression and PGI₂ levels [2]. Similarly, in human vascular smooth muscle cells exposed to IL-1 β , hypoxia overcame the inhibitory effects of IL-1 β and increased PGI₂ production [5]. Hypoxia alone in these same cells elevated PGIS expression and PGI₂ levels. These findings suggest that hypoxia could drive an adaptive response in vascular cells and plays a role in protecting vascular cells when inflammation is present [5].

3.5. Emphysema. PGIS expression was lower in arteriolar endothelium of human emphysema lung tissue compared with normal lung [28]. Cigarette smoke extract suppressed PGIS gene expression suggesting that its decrease could lead to deleterious effects on lung vasculature in this setting. Mice exhibiting overexpression of PGIS in the pulmonary vasculature had decreased endothelial cell apoptosis after chronic tobacco smoke exposure [28]. Cigarette smoke extract may bind to CpG sites in DNA leading to disruption of transcriptional regulation suggesting a mechanism for the minimization of PGIS gene expression.

3.6. Cytokine-Mediated Inflammation. IL-1 β , TGF- β , and bradykinin, in human pulmonary artery smooth muscle, decreased the production of cAMP in response to subsequent administration of PGI₂ analogues, providing data that inflammation can impair the actions of PGI₂ analogues in pulmonary hypertension treatment [14]. IL-1 β , TGF- β , and bradykinin also decreased adenylyl cyclase mRNA and

increased G- α inhibitory (G α_i) protein levels with subsequent reduction in IP mRNA expression [14]. Importantly, this could be a rationale for the development of tolerance to PGI₂ analogue medications.

Cytokine toxicity is mediated in many cell types through the arachidonic acid metabolism pathway via inducible COX-2 production [3]. Proinflammatory cytokines are major effectors of programmed cell death in the development of type 1 diabetes mellitus. Using a model of human insulin producing pancreatic β cells, PGIS overexpression protected against cytokine toxicity via decreased activation of the transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B) and subsequent prevention of inducible nitric oxide synthase (iNOS) and decreased cytokine-induced caspase-3 activation. Therefore, low-endogenous PGIS expression may have a pathogenic part in the development of pancreatic β cell death [3].

3.7. Fibrosis. PGI₂ has regulatory effects on fibroblast proliferation. For example, in a bleomycin-induced pulmonary fibrosis mouse model, PGI₂ functioned as an antiproliferative molecule preventing an increase in fibroblasts and providing protection against loss of lung function [17]. Similarly, in an additional mouse model of bleomycin-induced pulmonary fibrosis, mice treated with iloprost had a significant reduction in airway and pulmonary parenchyma inflammatory cells and deposition of collagen with improvement in lung static compliance, tissue elastance, and overall survival [29]. The proposed mechanism for these changes is the upregulation of antifibrotic mediators such as interferon- γ (IFN- γ), the chemokine CXCL10, and the downregulation of proinflammatory and profibrotic cytokines such as TNF- α , IL-6, and TGF- β [29].

Using a mouse model of PGIS overexpression specifically in lung epithelium, mortality related to bleomycin-induced acute lung injury was decreased [30]. In addition to decreased mortality, there was a reduction in parenchymal consolidation, apoptosis of lung tissue and weight loss. These findings were explained by *in vitro* and *in vivo* PGI₂ induced expression of NAD(P)H: quinone oxidoreductase 1 (Nqo1), an enzyme known to inhibit the generation of reactive oxygen species and therefore protective against oxidative stress. The PGIS-overexpressing mice had elevated levels of this antioxidant prior to administration of bleomycin and afterwards [30]. Taken together, these three studies suggest that PGI₂ may provide protection against bleomycin-induced lung injury.

3.8. Viral Infection. Signaling through IP had protective effects in the setting of respiratory syncytial virus (RSV) infection in a mouse model and one study suggests it may be beneficial in human disease. During RSV infection, in a mouse model of overexpressed PGIS in bronchial epithelium, weight loss, viral replication, and IFN- γ production were all decreased compared to controls [31]. Histopathology results showed decreased pulmonary edema. In contrast, IP-deficient mice had longer more severe illness with prolonged viral replication [31].

RSV infection also elevated a urinary metabolite of PGI₂ in human infants [32] suggesting PGI₂ may modulate virally-induced illness in people. Low numbers of a genetic polymorphism in the PGIS gene with subsequent decreased urinary PGI₂ metabolite levels, described as a genetic 9-base variable-number tandem repeat (VNTR), were correlated with more severe RSV infection. Infants with greater VNTR had less severe RSV-induced infections. Therefore, an association between lower numbers of PGIS VNTR repeats and increased severity of RSV infection identifies a host genetic factor associated with RSV disease severity [32]. Both of these studies support a protective role for PGI₂ in RSV-induced illness and suggest a possible therapy for acute RSV infection.

3.9. Rheumatoid Arthritis. In contrast to the seemingly anti-inflammatory properties of PGI₂, there is still debate about its effect in the setting of specific conditions [16, 33, 34]. PGI₂ and PGE₂ have been questioned as causative factors in inflammation as levels are increased in inflammatory tissues. The synovial fluid of rheumatoid arthritis (RA) patients has rich quantities of PGI₂ but the exact role of PGI₂ in RA is not fully understood [33, 34]. In a mouse model of chronic RA, IP-deficient mice were subjected to collagen-induced arthritis and had significantly decreased clinical and histologic arthritic scores despite anticollagen antibodies and complement activation similar to wild-type mice [34]. These mice were noted to have decreased levels of IL-6 in their arthritic paws. Administration of an IP agonist elevated the inflammatory cytokine IL-6 and amplified arthritis related genes such as IL-11, VEGF, FGF-2, and RANKL, increasing inflammation in the joint. Elevated IL-6 led to proliferation of the synovium, maturation of B cells, and formation of osteoclasts, all important in the pathogenesis of RA [34]. Importantly, signaling through the IP receptor required the presence of inflammatory IL-1 β for many of its effects in RA. One mechanism proposed for the effects of increased PGI₂ was the enhanced production of IL-6 via activated synovial fibroblasts in the setting of IL-1 β . Lack of elevated IL-6 due to IL-1 β explains why patients receiving PGI₂ agonists, for example, due to PAH, do not exhibit an increase in arthritic symptoms as a side effect. The results of this study are intriguing because PGI₂ was traditionally thought to play a role in the mediation of acute inflammation, but its role in chronic inflammation has been less studied [34].

Similarly, in an IP-deficient mouse model of collagen-antibody induced chronic inflammatory arthritis, the reduction in arthritis scores was 91% compared to a wild-type control group [33]. When a highly selective IP antagonist was used in a RA mouse model, it decreased pain similar to use of NSAIDs [33]. Therefore, it appears that signaling through the IP receptor, in the setting of RA, may increase inflammation in the joint. Currently, it is believed that both PGI₂ and PGE₂ are the primary prostaglandins involved in the inflammatory pain response in RA and this provides a rationale for the empiric use of NSAIDs and COX inhibitors for treatment of chronic arthritis.

4. PGI₂ Regulation of the Immune System

4.1. PGI₂ Regulation of the Innate Immune System. PGI₂ regulates both innate and adaptive immunity and its effects are, for the most part, anti-inflammatory or immunosuppressive in nature. PGI₂ modulates the function of dendritic cells, macrophages, monocytes, endothelial cells and eosinophils [35–41]. We will now review this data.

Dendritic cells are an important bridge between the innate and the adaptive immune system. PGI₂ analogues decreased mouse bone marrow derived dendritic cell (BMDC) maturation, function, and proinflammatory cytokine production after LPS stimulation. PGI₂ analogues also increased production of anti-inflammatory IL-10 and diminished chemokine production in mice suggesting an overall anti-inflammatory effect [42]. In a dose-dependent fashion, PGI₂ analogues, decreased secretion of TNF- α , IL-1 α , IL-6, and IL-12 *in vitro*. After LPS stimulation, both iloprost and cicaprost decreased levels of costimulatory molecules CD86, CD40, and MHC class II molecules on BMDC. The BMDC had a diminished ability to activate antigen-specific CD4 T cells of DO11.10 mice and led to reduced IL-4 and IL-5 production by the CD4 cells after iloprost and cicaprost treatment [42]. When the biological activity of iloprost on human monocytes-derived dendritic cells was examined, similar findings were identified. In a dose dependent fashion, iloprost inhibited the secretion of TNF- α , IL-6, IL-8, and IL-12 by monocytes-derived dendritic cells and increase secretion of IL-10 [39].

PGI₂ analogues produced a differential pattern of regulation on alveolar versus peritoneal rat macrophages suggesting variation in immunomodulatory effects of these agents on these specific cell types. Using a well characterized FcR-mediated model of phagocytosis, activation of the IP receptor inhibited phagocytosis of IgG-opsonized targets in peritoneal macrophages to a much greater extent compared to alveolar macrophages [35]. In addition, under conditions of LPS treatment, peritoneal macrophages increased production of IL-6 after administration of iloprost or carbaprostacyclin, but alveolar macrophages did not increase production to the same degree. Iloprost and carbaprostacyclin also significantly inhibited peritoneal macrophage of bacterial killing when compared to alveolar macrophages. A postulated reason for the differences is the differential expression of IP receptors on the two macrophage cell types and different receptor binding properties of PGI₂ analogues [35].

In addition to its effects on mouse innate immune cells, PGI₂ also has important regulatory effects on human dendritic cells. Iloprost increased IL-10 expression but inhibited toll-like receptor-mediated expression of TNF- α and IFN- α in human plasmacytoid dendritic cells suggesting an overall anti-inflammatory role [36]. Iloprost may, therefore, increase the tolerogenic ability of plasmacytoid dendritic cells and could potentially be useful in asthma treatment. Human follicular dendritic cells, found in germinal centers of secondary lymphoid follicles, strongly express PGIS and are able to produce PGI₂. Application of beraprost significantly reduced T cell proliferation stimulated by anti-CD3 antibody and, therefore, production of PGI₂ in the germinal centers may be

a mechanism for controlling T cell numbers [38] suggesting a reason why T cells constitute a smaller population when compared to B cells in the germinal centers. Iloprost reduced IFN- γ and IL-6 induced MCP-1, IL-8, RANTES, and TNF- α production in human monocytes [40]. STAT1 activation, critical in cardiovascular inflammation, was reduced with iloprost administration and led to decreased IFN- γ induced MCP-1 expression and therefore iloprost had an overall anti-inflammatory effect [40].

The evaluation of PGI₂ analogues on the expression of Th1 and Th2 related chemokines has also been ongoing as chemokines are known to play a role in the development of asthma [43]. Monocytes are main contributors of chemokines. Human monocytes were pretreated with iloprost and treprostinil prior to LPS stimulation and then evaluated for production of Th1-related chemokines interferon- γ -inducible protein-10 (IP-10/CXCL10) and Th2-related chemokine macrophage-derived chemokine (MDC/CCL22). The PGI₂ analogues decreased IP-10 production, but enhanced MDC. The enhancement of MDC suggests that use of PGI₂ analogues could potentially increase Th2 inflammation [43].

Lastly, in a model using human lung microvascular endothelial cells, eosinophils and the chemoattractants eotaxin and C5a, PGI₂ inhibited eosinophilic migration through the endothelial barrier by affecting their chemotaxis, adhesion, and transmigration and by strengthening the endothelial barrier [37]. Chemotaxis was limited by direct stimulation of the IP receptor on eosinophils as PGI₂ caused upregulation of cAMP leading to an increase in adenylyl cyclase despite use of chemoattractants such as eotaxin and C5a. Rapid upregulation of eotaxin-induced CD11b adhesion molecule was diminished by PGI₂ leading to decreased adhesion to fibronectin. PGI₂ also prevented eosinophil transmigration by strengthening endothelial barrier function. These findings were reversed by exposing eosinophils and endothelium to an IP antagonist [37]. These studies are important because they suggest a role for PGI₂ in the maintenance of the endothelial barrier and the prevention of allergic disease.

4.2. PGI₂ Regulation of the Adaptive Immune System. Currently, it is widely believed that signaling through the IP receptor has immunosuppressive properties. PGI₂ analogues play a key role via inhibition of Th1 and Th2 cytokine production from CD4 T cells [21, 42] although the specifics remain controversial as we will see in the discussion below. B cells are also influenced by analogues of PGI₂ and are discussed at the end of this section.

In a mouse study using PGI₂ analogues, cicaprost and iloprost, IFN- γ from Th1 cells and IL-4, IL-10, and IL-13 from Th2 cells were diminished in a dose dependent manner [41]. Elevated cAMP levels and downregulation of NF- κ B correlated with the inhibition of these cytokines. These findings suggest an immunosuppressive capability of PGI₂ analogues [41]. In IP-deficient mice subjected to a chronic contact hypersensitivity model showed a significantly decreased contact hypersensitivity response [44].

TABLE 1: Therapeutic use of PGI₂—approved agents.

| Agent | Pharmacology | Indications |
|--------------|------------------------------------|--|
| Epoprostenol | Synthetic salt of PGI ₂ | PAH, transplantation, renal dialysis, and extracorporeal circulation systems |
| Treprostinil | IP receptor agonist | PAH |
| Iloprost | IP receptor agonist | PAH |

In contrast to the study above, iloprost promoted Th1 cells differentiation suggesting that PGI₂-IP-signaling promotes contact hypersensitivity. Promotion of Th1 differentiation was decreased by a PKA inhibitor suggesting mediation through the cAMP-PKA pathway [44]. These findings suggest a role for PGI₂ in the promotion of Th1 pathology, which is in opposition to findings suggesting that it has more immunosuppressive effects.

In addition to immunomodulatory effects on T cells, PGI₂ regulates B cell function. In activated B cells, beraprost increased the costimulatory molecule CD86 via the IP receptor with subsequent elevation in cAMP [45]. CD86 is important as it acts as a costimulatory molecule required for T cell activation specifically Th2 activation. Its expression is elevated on B cells in the light zone of germinal center where some Th2 cells are found. Increased T cell proliferation was noted after exposure to beraprost treated B cells [45] and suggests a role for beraprost as an adjuvant in vaccine development.

5. Therapeutic Use of PGI₂

PGI₂ has a long history of use for the treatment of pulmonary arterial hypertension (PAH) [14, 16, 28]. Regrettably, its efficacy has been less than expected possibly due to the development of tolerance. A postulated mechanism for the development of tolerance is the impaired production of PGI₂ in the setting of increased thromboxane synthesis, which is also thought to be an initial step in the pathogenesis of PAH. Nonetheless, it is one of the main therapies in severe idiopathic PAH and has been shown to improve overall survival.

Epoprostenol, treprostinil, and iloprost are approved for the treatment of PAH [46] (see Table 1). Their use in PAH has been investigated since 1980 and their initial use in long-term therapy began in 1984 in the research setting. Intravenous formulations are nonselective and can cause both pulmonary and systemic hypotension via vasodilation. Side effects shared by these medications include headache, flushing, hypotension, jaw pain with initial mastication, diarrhea, nausea, musculoskeletal pain of the legs and feet, and an erythematous blotchy skin rash [46].

Epoprostenol (Flolan), a stable freeze dried synthetic salt of PGI₂, is also used in transplantation, renal dialysis, and extracorporeal circulation systems as it is an effective inhibitor of platelet aggregation. It was the first prostanoid approved for use in the treatment in PAH by the FDA in 1995 and is currently the most commonly used PGI₂ analogue [46]. It has a very short half life of 6 minutes *in vivo*. Any

interruption of its infusion can cause severe rebound pulmonary hypertension and even death. Tolerance may develop over time. Due to its unstable nature requiring a continuous intravascular infusion, its use as an antithrombotic in the general population has been limited.

Treprostinil (Remodulin) was approved for use by the FDA in 2002 and is a potent IP receptor agonist. It is administered as a continuous subcutaneous (SQ) or IV infusion or an inhaled formulation and provides a long-term survival benefit in patients with idiopathic PAH. Pain at the site of administration when given SQ has limited this form of administration. The inhaled form given 4 times per day was approved for use in 2009. Currently, an oral form of treprostinil is being investigated. Overall, treprostinil has fewer side effects when compared to epoprostenol [46] and a longer half life of about 4 hours.

Iloprost (Ventavis), a PGI₂ analogue and potent IP receptor agonist, received FDA approval in 2004. It is administered via nebulization 6–9 times per day requiring 10–15 minutes per administration. Its half life is about 20–30 minutes. Administration via inhalation limits side effects such as systemic hypotension. Inhaled iloprost can cause the development of reactive airway obstruction therefore limiting its use [46].

Cicaprost is a synthetic PGI₂ analogue which is metabolically stable and bioavailable after oral administration. It is currently used in the research setting [46].

Beraprost is a stable, orally active PGI₂ analogue, used experimentally in the treatment of primary pulmonary hypertension, peripheral occlusive disease, ischemia, reperfusion injury, and in the vascular complication of diabetes mellitus [7]. Beraprost has a high-affinity binding to the human IP receptor and a longer half life of about 1 hour [45]. Benefits of beraprost have been shown in short-term trials but it appears to have attenuated effects in longer treatment courses [46].

5.1. Potential New Therapeutic Options. ONO-1301 is a novel nonprostanoid long-acting PGI₂ agonist that is currently being used in the research setting. It has both PGI₂ activity and thromboxane synthase inhibitory activity [47]. It is unlike PGI₂ as it does not contain a five-membered ring and allylic alcohol. This property adds to its stability and allows the drug to be given two times per day as a subcutaneous injection. In mouse studies, it diminished pulmonary fibrosis associated with bleomycin intratracheal injection and improved survival rates. In addition, it decreased the total cell count, neutrophil count, thromboxane B2, and total protein level in BAL fluid and inhibit ICAM-1 and VCAM-1 adhesion molecule expression in the lung tissue

[47]. Therefore, it may be a prospective candidate in the treatment of idiopathic pulmonary fibrosis in the future.

Taken together, PGI₂ functions mostly as an immunoinhibitor molecule through multiple cell types such as dendritic cells, macrophages, and T-cells.

Abbreviations

| | |
|---------------------|---|
| ALT: | Alanine aminotransferase |
| BMDC: | Bone marrow dendritic cells |
| CCL17: | Chemokine (C-C motif) ligand 17 |
| 13- <i>cis</i> -RA: | 13- <i>cis</i> -retinoic acid |
| CD: | Clusters of differentiation |
| ConA: | Concanavalin A |
| CXCL10: | C-X-C motif chemokine 10 |
| cAMP: | Cyclic adenosine monophosphate |
| COX: | Cyclooxygenase |
| FGF-2: | Fibroblast growth factor |
| FDA: | Food and Drug Administration |
| Gα _i : | Guanosine nucleotide-binding-α-inhibitory protein |
| Gα _s : | Guanosine nucleotide-binding α-stimulatory protein |
| iNOS: | Inducible nitric oxidase synthase |
| IgE: | Immunoglobulin-E |
| IFN-γ: | Interferon-γ |
| IL: | Interleukin |
| LPS: | Lipopolysaccharide |
| MDC: | Macrophage derived chemokine |
| MHC: | Major histocompatibility complex |
| mRNA: | Messenger RNA |
| miRNA: | Micro-RNA |
| MCP-1: | Monocyte chemoattractant protein-1 |
| mPGES-1: | Membrane-associated PGE synthase-1 |
| Nqo 1: | NADP(H) : Quinone oxide reductase |
| NKT: | Natural killer T cells |
| NSAIDs: | Nonsteroidal anti-inflammatory |
| NF-κB: | Nuclear factor kappa-light-chain-enhancer of activated B cells |
| OA: | Osteoarthritis |
| OVA: | Ovalbumin |
| PPAR: | Peroxisome proliferators activated receptor |
| IP: | Prostacyclin receptor |
| PGIS: | Prostacyclin synthase |
| PGI ₂ : | Prostacyclin |
| PG: | Prostaglandin |
| PKA: | Protein kinase A |
| PAH: | Pulmonary arterial hypertension |
| RANKL: | Receptor activator of nuclear factor kappa-B ligand |
| RANTES: | Regulated upon activation, normal Tcell expressed, and secreted protein |
| RSV: | Respiratory syncytial virus |
| RA: | Rheumatoid arthritis |
| STAT: | Signal transducers and activators of transcription |
| SQ: | Subcutaneous |
| Th1: | T helper type 1 T cells |
| Th2: | T helper type 2 T cells |

TGF-β: Transforming growth factor-β

TNF-α: Tumor necrosis factor-α

VNTR: Variable-number tandem repeat

VEGF: Vascular endothelial growth factor.

Acknowledgments

This work was supported by National Institutes of Health Grants U19 AI095227, R01 HL 090664, R01 AI 070672, R01 AI 059108, R21 HL106446, and K12HD043483-08 and Veteran Affairs Grant 1101BX000624.

References

- [1] P. Needleman, S. Moncada, S. Bunting, J. R. Vane, M. Hamberg, and B. Samuelsson, "Identification of an enzyme in platelet microsomes which generates thromboxane A₂ from prostaglandin endoperoxides," *Nature*, vol. 261, no. 5561, pp. 558–560, 1976.
- [2] M. Camacho, C. Rodríguez, J. Salazar et al., "Retinoic acid induces PGI synthase expression in human endothelial cells," *Journal of Lipid Research*, vol. 49, no. 8, pp. 1707–1714, 2008.
- [3] E. Gurgul-Convey and S. Lenzen, "Protection against cytokine toxicity through endoplasmic reticulum and mitochondrial stress prevention by prostacyclin synthase overexpression in insulin-producing cells," *The Journal of Biological Chemistry*, vol. 285, no. 15, pp. 11121–11128, 2010.
- [4] Z. Jaffar, K. S. Wan, and K. Roberts, "A key role for prostaglandin I₂ in limiting lung mucosal Th2, but not Th1, responses to inhaled allergen," *Journal of Immunology*, vol. 169, no. 10, pp. 5997–6004, 2002.
- [5] M. Camacho, C. Rodríguez, A. Guadall et al., "Hypoxia up-regulates PGI-synthase and increases PGI₂ release in human vascular cells exposed to inflammatory stimuli," *Journal of Lipid Research*, vol. 52, no. 4, pp. 720–731, 2011.
- [6] T. Matsuoka and S. Narumiya, "The roles of prostanoids in infection and sickness behaviors," *Journal of Infection and Chemotherapy*, vol. 14, no. 4, pp. 270–278, 2008.
- [7] H. Yin, L. Cheng, R. Langenbach, and C. Ju, "Prostaglandin I₂ and E₂ mediate the protective effects of cyclooxygenase-2 in a mouse model of immune-mediated liver injury," *Hepatology*, vol. 45, no. 1, pp. 159–169, 2007.
- [8] K. M. Egan, J. A. Lawson, S. Fries et al., "COX-2-derived prostacyclin confers atheroprotection on female mice," *Science*, vol. 306, no. 5703, pp. 1954–1957, 2004.
- [9] Y. Hui, E. Ricciotti, I. Crichton et al., "Targeted deletions of cyclooxygenase-2 and atherogenesis in mice," *Circulation*, vol. 121, no. 24, pp. 2654–2660, 2010.
- [10] V. L. King, D. B. Trivedi, J. M. Gitlin, and C. D. Loftin, "Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 26, no. 5, pp. 1137–1143, 2006.
- [11] M. H. Zou and V. Ullrich, "Peroxy-nitrite formed by simultaneous generation of nitric oxide and superoxide selectively inhibits bovine aortic prostacyclin synthase," *The FEBS Letters*, vol. 382, no. 1–2, pp. 101–104, 1996.
- [12] M. Zou, C. Martin, and V. Ullrich, "Tyrosine nitration as a mechanism of selective inactivation of prostacyclin synthase by peroxy-nitrite," *Biological Chemistry*, vol. 378, no. 7, pp. 707–713, 1997.

- [13] M. I. Wade, N. F. Voelkel, and F. A. Fitzpatrick, "Suicide inactivation of prostaglandin I₂ synthase: characterization of mechanism-based inactivation with isolated enzyme and endothelial cells," *Archives of Biochemistry and Biophysics*, vol. 321, no. 2, pp. 453–458, 1995.
- [14] H. El-Haroun, D. L. Clarke, K. Deacon et al., "IL-1 β , BK, and TGF- β 1 attenuate PGI₂-mediated cAMP formation in human pulmonary artery smooth muscle cells by multiple mechanisms involving p38 MAP kinase and PKA," *American Journal of Physiology*, vol. 294, no. 3, pp. L553–L562, 2008.
- [15] A. Mohite, A. Chillar, S. P. So, V. Cervantes, and K. H. Ruan, "Novel mechanism of the vascular protector prostacyclin: regulating microRNA expression," *Biochemistry*, vol. 50, no. 10, pp. 1691–1699, 2011.
- [16] R. J. Soberman and P. Christmas, "Revisiting prostacyclin: new directions in pulmonary fibrosis and inflammation," *American Journal of Physiology*, vol. 291, no. 2, pp. L142–L143, 2006.
- [17] A. K. Lovgren, L. A. Jania, J. M. Hartney et al., "COX-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis," *American Journal of Physiology*, vol. 291, no. 2, pp. L144–L156, 2006.
- [18] S. K. Dahlen, G. Hansson, P. Hedqvist, T. Bjorck, E. Granstrom, and B. Dahlen, "Allergen challenge of lung tissue from asthmatic elicits bronchial contraction that correlates with the release of leukotrienes C₄, D₄, and E₄," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 80, no. 6, pp. 1712–1716, 1983.
- [19] E. S. Schulman, H. H. Newball, L. M. Demers, F. A. Fitzpatrick, and N. F. Adkinson Jr., "Anaphylactic release of thromboxane A₂, Prostaglandin D₂, and prostacyclin from human lung parenchyma," *American Review of Respiratory Disease*, vol. 124, no. 4, pp. 402–406, 1981.
- [20] Y. Takahashi, S. Tokuoka, T. Masuda et al., "Augmentation of allergic inflammation in prostanoid IP receptor deficient mice," *British Journal of Pharmacology*, vol. 137, no. 3, pp. 315–322, 2002.
- [21] K. Nagao, H. Tanaka, M. Komai, T. Masuda, S. Narumiya, and H. Nagai, "Role of prostaglandin I₂ in airway remodeling induced by repeated allergen challenge in mice," *American Journal of Respiratory Cell and Molecular Biology*, vol. 29, no. 3, pp. 314–320, 2003.
- [22] Z. Jaffar, M. E. Ferrini, M. C. Buford, G. A. FitzGerald, and K. Roberts, "Prostaglandin I₂-IP signaling blocks allergic pulmonary inflammation by preventing recruitment of CD4⁺ Th2 cells into the airways in a mouse model of asthma," *Journal of Immunology*, vol. 179, no. 9, pp. 6193–6203, 2007.
- [23] M. Wang, P. R. Cooper, M. Jiang et al., "Deletion of microsomal prostaglandin E synthase-1 does not alter ozone-induced airway hyper-responsiveness," *Journal of Pharmacology and Experimental Therapeutics*, vol. 334, no. 1, pp. 63–68, 2010.
- [24] M. Idzko, H. Hammad, M. van Nimwegen et al., "Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function," *Journal of Clinical Investigation*, vol. 117, no. 2, pp. 464–472, 2007.
- [25] L. D. Madison, J. M. Scarlett, P. Levasseur et al., "Prostacyclin signaling regulates circulating ghrelin during acute inflammation," *Journal of Endocrinology*, vol. 196, no. 2, pp. 263–273, 2008.
- [26] J. Vane and R. E. Corin, "Prostacyclin: a vascular mediator," *European Journal of Vascular and Endovascular Surgery*, vol. 26, no. 6, pp. 571–578, 2003.
- [27] C. Lehmann, J. P. König, J. Dettmann, J. Birnbaum, and W. J. Kox, "Effects of iloprost, a stable prostacyclin analog, on intestinal leukocyte adherence and microvascular blood flow in rat experimental endotoxemia," *Critical Care Medicine*, vol. 29, no. 7, pp. 1412–1416, 2001.
- [28] S. P. Nana-Sinkam, D. L. Jong, S. Sotto-Santiago et al., "Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke," *American Journal of Respiratory and Critical Care Medicine*, vol. 175, no. 7, pp. 676–685, 2007.
- [29] Y. Zhu, Y. Liu, W. Zhou et al., "A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice," *Respiratory Research*, vol. 11, article 34, 2010.
- [30] W. Zhou, D. R. Dowell, M. W. Geraci et al., "PGI synthase overexpression protects against bleomycin-induced mortality and is associated with increased Nqo 1 expression," *American Journal of Physiology*, vol. 301, no. 4, pp. L615–L622, 2011.
- [31] K. Hashimoto, B. S. Graham, M. W. Geraci et al., "Signaling through the prostaglandin I₂ receptor IP protects against respiratory syncytial virus-induced illness," *Journal of Virology*, vol. 78, no. 19, pp. 10303–10309, 2004.
- [32] K. Hashimoto, K. Ishibashi, T. Gebretsadik et al., "Functional polymorphism of the promoter region of the prostacyclin synthase gene and severity of RSV infection in hospitalized children," *Journal of Medical Virology*, vol. 80, no. 11, pp. 2015–2022, 2008.
- [33] A. M. Pulichino, S. Rowland, T. Wu et al., "Prostacyclin antagonism reduces pain and inflammation in rodent models of hyperalgesia and chronic arthritis," *Journal of Pharmacology and Experimental Therapeutics*, vol. 319, no. 3, pp. 1043–1050, 2006.
- [34] T. Honda, E. Segi-Nishida, Y. Miyachi, and S. Narumiya, "Prostacyclin-IP signaling and prostaglandin E₂-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis," *Journal of Experimental Medicine*, vol. 203, no. 2, pp. 325–335, 2006.
- [35] D. M. Aronoff, C. M. Peres, C. H. Serezani et al., "Synthetic prostacyclin analogs differentially regulate macrophage function via distinct analog-receptor binding specificities," *Journal of Immunology*, vol. 178, no. 3, pp. 1628–1634, 2007.
- [36] C. H. Hung, Y. T. Chu, J. L. Suen et al., "Regulation of cytokine expression in human plasmacytoid dendritic cells by prostaglandin I₂ analogues," *European Respiratory Journal*, vol. 33, no. 2, pp. 405–410, 2009.
- [37] V. Konya, E. M. Sturm, P. Schratl et al., "Endothelium-derived prostaglandin I₂ controls the migration of eosinophils," *Journal of Allergy and Clinical Immunology*, vol. 125, no. 5, pp. 1105–1113, 2010.
- [38] I. Y. Lee, E. M. Ko, S. H. Kim, D. I. Jeoung, and J. Choe, "Human follicular dendritic cells express prostacyclin synthase: a novel mechanism to control T cell numbers in the germinal center," *Journal of Immunology*, vol. 175, no. 3, pp. 1658–1664, 2005.
- [39] T. Müller, T. Dürk, B. Blumenthal et al., "Iloprost has potent anti-inflammatory properties on human monocyte-derived dendritic cells," *Clinical and Experimental Allergy*, vol. 40, no. 8, pp. 1214–1221, 2010.
- [40] D. Strassheim, S. R. Riddle, D. L. Burke, M. W. Geraci, and K. R. Stenmark, "Prostacyclin inhibits IFN- γ -stimulated cytokine expression by reduced recruitment of CBP/p300 to STAT1 in a SOCS-1-independent manner," *Journal of Immunology*, vol. 183, no. 11, pp. 6981–6988, 2009.
- [41] W. Zhou, T. S. Blackwell, K. Goleniewska et al., "Prostaglandin I₂ analogs inhibit Th1 and Th2 effector cytokine production by CD4 T cells," *Journal of Leukocyte Biology*, vol. 81, no. 3, pp. 809–817, 2007.
- [42] W. Zhou, K. Hashimoto, K. Goleniewska et al., "Prostaglandin I₂ analogs inhibit proinflammatory cytokine production and

- T cell stimulatory function of dendritic cells," *Journal of Immunology*, vol. 178, no. 2, pp. 702–710, 2007.
- [43] C. H. Kuo, Y. C. Ko, S. N. Yang et al., "Effects of PGI₂ analogues on Th1- and Th2-related chemokines in monocytes via epigenetic regulation," *Journal of Molecular Medicine*, vol. 89, no. 1, pp. 29–41, 2011.
- [44] S. Nakajima, T. Honda, D. Sakata et al., "Prostaglandin I₂-IP signaling promotes Th1 differentiation in a mouse model of contact hypersensitivity," *Journal of Immunology*, vol. 184, no. 10, pp. 5595–5603, 2010.
- [45] J. Kim, C. S. Park, C. H. Park, D. I. Jeoung, Y. M. Kim, and J. Choe, "Beraprost enhances the APC function of B cells by upregulating CD86 expression levels," *Journal of Immunology*, vol. 186, no. 7, pp. 3866–3873, 2011.
- [46] D. D. Ivy, "Prostacyclin in the intensive care setting," *Pediatric Critical Care Medicine*, vol. 11, no. 2, pp. S41–S45, 2010.
- [47] S. Murakami, N. Nagaya, T. Itoh et al., "Prostacyclin agonist with thromboxane synthase inhibitory activity (ONO-1301) attenuates bleomycin-induced pulmonary fibrosis in mice," *American Journal of Physiology*, vol. 290, no. 1, pp. L59–L65, 2006.



Hindawi
Submit your manuscripts at
<http://www.hindawi.com>

